Pernix Therapeutics Cash Flow - Quarterly (NASDAQ:PTX)

Add to My Stocks
$2.44 $0.02 (0.83%) PTX stock closing price Jun 20, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Pernix Therapeutics needs to disclose. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Pernix Therapeutics profits one has to check the income statement and for Pernix Therapeutics debt one has to check the balance sheet. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Pernix Therapeutics stock analysis. Pernix Therapeutics generated $-0.26M cash from operating activities in till this quarter of 2018 Q1. The cash from operating activities for Pernix Therapeutics is $ 2018 Q1, which saw an increase from previous quarter.

View and download details of Pernix Therapeutics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow12.04M81.91M61.27M41M20.54M92.24M69.95M47.71M25.14M99.71M
Net Increase (Decrease) in Assets Liabilities5.12M-3.5M-2.99M-0.05M6.67M22.73M1.84M-8.44M-4.23M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net1.14M-7.2M-22.78M-1.44M38.1M-11.17M-12.39M-10.96M38.09M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment--0.01M-0.01M---0.98M-0.96M-0.94M-0.22M-1.21M
Acquisition Disposition of Subsidiaires------0.58M----87.98M
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities-2M-----0.58M-0.58M-4.85M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares-1.97M1.12M--19.81M18.3M11.35M--
Issuance (Repayment) of Debt Securities-5.38M11.93M12.43M-12.85M-12.83M-20.48M-20.45M-14.93M-14.92M119.94M
Increase (Decrease) in Bank & Other Borrowings------1M-1M-1M-1M7.65M
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-0.22M-13.69M-13.65M---0.02M-0.02M-0.02M-0.01M-7.61M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year36.37M56.13M34.85M15.64M23.02M34.55M8.26M4.57M8M7.39M
Cash & Equivalents at Year End26.94M32.82M27.24M14.34M22.73M36.37M28.52M29.2M36.64M56.13M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Pernix Therapeutics stock price history and Pernix Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Pernix Therapeutics has cash of $26.94M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Pernix Therapeutics stock price.
  • Pernix Therapeutics decreased its cash from operating activities to $-0.26M till 2018 Q1. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $- for PTX till last quarter 2018 Q1 report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Pernix Therapeutics spent $-5.6M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Pernix Therapeutics Cash Flow

Quarterly Cash Flow Statements For Pernix Therapeutics Holdings Inc Peers

Cumberland Pharma cash flow, Depomed cash flow, Evoke Pharma cash flow, Vanda Pharmaceuticals cash flow, Versartis cash flow